Figure 4

Change in forced vital capacity (FVC) from baseline to 1 year after the start of antifibrotic therapy, by rs3750920 genotype. (A) Patients treated with nintedanib (n = 22). (B) Patients treated with pirfenidone (n = 14). (C) Patients treated with inhaled N-acetylcysteine (n = 7).